Literature DB >> 1827557

Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118-630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer.

W Kuber1, G Viehberger, R Zeillinger, J Spona.   

Abstract

In 20 patients with locally advanced or metastatic prostate cancer, testicular tissue obtained by bilateral subcapsular orchidectomy was examined for steroid hormone content and morphological changes. Eight patients (group I) had not received previous treatment. Twelve patients had been treated with monthly subcutaneous doses of the depot luteinizing hormone-releasing hormone (LHRH) agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118-630). Six patients (group II) had been treated for less than 6 months and 6 patients (group III) for more than 6 months. The longest duration of treatment with depot LHRH was 36 months. After 2 months of treatment (group II), maximum hormone suppression was achieved and remained unchanged even if treatment was continued for 3 years. The mean serum testosterone levels were decreased in group II (means = 0.586 mg/ml) and in group III (means = 0.575 mg/ml) and were found to be in the range of castration; a statistically significant reduction in luteinizing hormone (P less than 0.000001) and follicle-stimulating hormone (P less than 0.05) was observed in the treated patient groups. The content of the steroid hormones dihydroepiandrosterone sulfate (DHEA)-S, testosterone, androstenedione, oestradiol, progesterone and 17-alpha-hydroxyprogesterone/g testicular tissue was significantly lower in patients on LHRH agonists. The differences in concentration were particularly pronounced for DHEA-S, T and A. As in the case of serum concentrations, the testicular tissues showed no differences between groups II and III. In the treated groups a significant reduction in weight was seen, depending on the duration of therapy. Similarly, the structural changes visible by the aid of light and electron microscopes increased with the duration of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827557     DOI: 10.1007/bf00294016

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  17 in total

1.  Normal adults and subjects with hypogonadotropic hypogonadism respond differently to D-Ser(TBU)6-LH-RH-EA10.

Authors:  R Smith; R A Donald; E A Espiner; S G Stronach; I A Edwards
Journal:  J Clin Endocrinol Metab       Date:  1979-01       Impact factor: 5.958

2.  Extra-pituitary inhibition of testicular function by luteinising hormone releasing hormone.

Authors:  A J Hsueh; G F Erickson
Journal:  Nature       Date:  1979-09-06       Impact factor: 49.962

3.  Potent inhibitory activity of [D-Leu6, Des-Gly-NH2(10)]LHRH ethylamide on LH/hCG and PRL testicular receptor levels in the rat.

Authors:  C Auclair; P A Kelly; D H Coy; A V Schally; F Labrie
Journal:  Endocrinology       Date:  1977-12       Impact factor: 4.736

4.  An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.

Authors:  M R Robinson; L Denis; C Mahler; K Walker; R Stitch; G Lunglmayr
Journal:  Eur J Surg Oncol       Date:  1985-06       Impact factor: 4.424

5.  Inhibitory effects of a single intranasal administration of [D-Ser(TBU)6, des-Gly-NH210]LHRH ethylamide, a potent LHRH agonist, on serum steroid levels in normal adult men.

Authors:  A Bélanger; F Labrie; A Lemay; S Caron; J P Raynaud
Journal:  J Steroid Biochem       Date:  1980-02       Impact factor: 4.292

6.  Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.

Authors:  J A Smith
Journal:  J Urol       Date:  1984-06       Impact factor: 7.450

7.  Down-regulation of testicular androgen biosynthesis and LH receptor levels by an LHRH agonist: role of prolactin.

Authors:  A Belanger; C Auclair; C Seguin; P A Kelly; F Labrie
Journal:  Mol Cell Endocrinol       Date:  1979-01       Impact factor: 4.102

8.  Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone.

Authors:  J Sandow; W Von Rechenberg; G Jerzabek; W Stoll
Journal:  Fertil Steril       Date:  1978-08       Impact factor: 7.329

9.  Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.

Authors:  S R Ahmed; J Grant; S M Shalet; A Howell; S D Chowdhury; T Weatherson; N J Blacklock
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19

10.  Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630).

Authors:  P J Van Cangh; R J Opsomer
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

View more
  2 in total

Review 1.  Fertility preservation options in transgender people: A review.

Authors:  Natnita Mattawanon; Jessica B Spencer; David A Schirmer; Vin Tangpricha
Journal:  Rev Endocr Metab Disord       Date:  2018-09       Impact factor: 6.514

Review 2.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.

Authors:  R N Brogden; D Faulds
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.